TNFRSF17 and Miyoshi myopathy: Overall, these data define a population of MM in which the loss of plasma cell identity promotes primary resistance to therapies that depend on plasma cell biology, including immunomodulatory drugs (IMiDs), anti-BCMA, and anti-CD38 agents.37